 Primary objective is to assess the overall response rate ORR after induction therapy with docetaxel in combination with CDDP and cetuximab in patients with NSCLC stage IB, II, and IIIa. ORR will be determined by the percentage of patients achieving objective response rates CR PR according to the RECIST guidelines. 